Researchers urged hospitals to set up processes for updating pharmacogenomic results, but it's unclear how frequently that ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

The firm will use the proceeds to advance AIR-001 as its lead candidate and file a clinical trial application later this year.

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...

Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

The organizations launched the clinical trial to assess clinical utility of whole-genome sequencing in cardiovascular disease ...

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...